Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AIRISE-siKRAS-NP
- Development stage
- Preclinical
- Lead developer
- PDX Pharmaceuticals
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
AIRISE-siKRAS-NP is an investigational therapeutic candidate developed by PDX Pharmaceuticals, utilizing its proprietary **AIRISE** (Augmented Immune Response and Inhibitor SEnsitive) nanoparticle platform. The drug is designed to deliver small interfering RNA (siRNA) that specifically targets and silences the **KRAS** oncogene. KRAS mutations are primary drivers in several aggressive malignancies, including pancreatic, colorectal, and non-small cell lung cancers. By encapsulating the siRNA within a nanoparticle, the formulation protects the genetic material from systemic degradation and facilitates targeted delivery to tumor cells. The AIRISE platform is engineered not only to inhibit the expression of the KRAS protein but also to potentially stimulate a localized anti-tumor immune response, thereby addressing both the oncogenic signaling and the immunosuppressive tumor microenvironment.
- Other names
- KRAS-siRNA nanoparticle
02
Targets
Kirsten rat sarcoma viral oncogene homolog mRNA
Beyond the preview
Go deeper on AIRISE-siKRAS-NP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AIRISE-siKRAS-NP.